No one knows exactly how rare retrograde cricopharyngeus dysfunction (R-CPD) is, because no population-level studies have ever measured its prevalence. The condition, sometimes called “no-burp syndrome,” was first formally described in 2019, and it still lacks its own diagnostic code in medical classification systems. What researchers can say is that it is almost certainly more common than the number of diagnosed cases suggests, since most people with R-CPD spend years being misdiagnosed or simply assuming their inability to burp is a personal quirk rather than a treatable medical condition.
Why There Are No Prevalence Numbers
R-CPD is too new to the medical literature for epidemiological data to exist. The first published case series appeared only in 2019, and as of 2025, researchers have noted a complete lack of epidemiological and pediatric studies on the condition. Without large-scale surveys asking people whether they can burp, or screening tools built into routine care, there is no way to estimate what percentage of the population is affected.
The condition also has no ICD-10 or ICD-11 code, which means it cannot be tracked through insurance claims or hospital databases the way other diagnoses can. Clinicians who recognize it must code it under a broader, less specific category. This absence from coding systems creates a statistical blind spot: even the patients who do get diagnosed are essentially invisible in health data.
Underdiagnosis Is Likely the Bigger Problem
Most R-CPD patients have been misdiagnosed with irritable bowel syndrome or gastroesophageal reflux disease before eventually finding the correct diagnosis, according to clinicians at NewYork-Presbyterian who specialize in treating the condition. The associated treatments for those conditions, unsurprisingly, do nothing to help. Many patients struggle for years to get a proper diagnosis because most doctors have never heard of R-CPD.
There are a few reasons the condition flies under the radar. The inability to burp sounds trivial to people who have never experienced it, so patients often feel dismissed. Symptoms like bloating, chest pain, and excessive gas overlap heavily with far more common gastrointestinal conditions. And because R-CPD wasn’t described in the medical literature until recently, it was not taught in medical schools or residency programs, meaning an entire generation of practicing physicians may not recognize it.
A strong clue that R-CPD is not vanishingly rare comes from online communities. Tens of thousands of people have found each other in forums and social media groups dedicated to the inability to burp, many describing identical symptom profiles before ever seeing a specialist. This doesn’t give us a number, but it strongly suggests the condition is underrecognized rather than exceptionally uncommon.
What R-CPD Looks Like
The core problem is straightforward. When you eat, drink, or swallow air, gas naturally accumulates in the stomach and esophagus. Normally, a ring of muscle at the top of the esophagus called the cricopharyngeus relaxes briefly to let that gas escape upward as a burp. In people with R-CPD, this muscle fails to relax in response to gas pressure. Air gets trapped, and instead of being released, it causes a cascade of uncomfortable symptoms.
In the original case series of 51 patients, the clinical picture was remarkably consistent. Fifty of 51 patients said they had been unable to burp for as long as they could remember. Forty-nine reported distension-related discomfort: sharp chest pain, abdominal bloating, and sometimes nausea, especially after eating. Fifty of 51 experienced gurgling noises from the chest, lower neck, or abdomen, an involuntary sound that occurs as trapped gas shifts around. And 43 of 51 reported excessive flatulence, since gas that cannot exit upward eventually works its way down.
It Typically Starts in Childhood
R-CPD does not usually develop later in life. In one case series of 50 patients, 58% reported that their symptoms began before age 10. Another 20% noticed them during their teenage years. Only a handful of patients traced their onset to their twenties or thirties, and just one patient in the study was older than 50 at the time of diagnosis. The median age at diagnosis was 27.5 years, meaning most people live with the condition for a decade or two before finding out it has a name.
There also appears to be a familial component. Across multiple studies, 28% of R-CPD patients reported at least one other family member with the same inability to burp. No genetic studies have been conducted yet, so it is unclear whether this reflects a heritable trait in the muscle itself or simply shared anatomy. The gender split is roughly even, with studies showing close to a 50/50 ratio of male and female patients.
The Daily Impact Is Significant
Because the primary symptom is the inability to do something most people never think about, R-CPD can sound minor from the outside. For the people living with it, the reality is different. In a quality-of-life study, 93% of patients reported socially awkward gurgling noises they could not control. Patients rated their embarrassment at 3.4 out of 5, anxiety and depression at 3.1, negative effects on relationships at 2.6, and disruption to work at 2.7. The bloating and chest pain after meals can be severe enough that people avoid eating in social settings or limit their diet to reduce gas production.
Treatment Works Well for Most People
The primary treatment is an injection of botulinum toxin into the cricopharyngeus muscle, which temporarily paralyzes it and allows gas to pass. This gives the body a window to “learn” the belching reflex. In the largest published case series of 200 patients, 99% experienced relief of their core symptoms after the injection. Of those, about 80% maintained the ability to burp after the medication’s direct effects wore off, with follow-up periods averaging nearly 20 months. The remaining patients who relapsed could receive a second injection.
Some clinicians also use a behavioral retraining protocol as a supplement to the injection. In a small study of seven patients, six achieved lasting symptom resolution when they combined the injection with specific positioning and eructation exercises during the recovery window. This approach is still being studied, but it may improve long-term success rates for people whose symptoms return after the initial treatment.
The injection itself is performed either under direct visualization with an endoscope or guided by imaging or electromyography, with doses typically ranging from 50 to 100 units of botulinum toxin. Most patients are treated as an outpatient procedure and begin noticing the ability to burp within a few days to a couple of weeks as the muscle relaxes.